Evaluation of RTS,S Malaria Vaccine in Children
Author Information
Author(s): Macete Eusebio V, Sacarlal Jahit, Aponte John J, Leach Amanda, Navia Margarita M, Milman Jessica, Guinovart Caterina, Mandomando Inacio, López-Púa Yolanda, Lievens Marc, Owusu-Ofori Alex, Dubois Marie-Claude, Cahill Conor P, Koutsoukos Marguerite, Sillman Marla, Thompson Ricardo, Dubovsky Filip, Ballou W Ripley, Cohen Joe, Alonso Pedro L
Primary Institution: Centro de Investigação em Saúde de Manhiça (CISM), Manhiça, Mozambique
Hypothesis
The study aims to evaluate the safety and immunogenicity of two formulations of the RTS,S malaria vaccine in children aged 3 to 5 years.
Conclusion
The RTS,S/AS02D vaccine is safe, well tolerated, and shows non-inferiority in antibody responses compared to RTS,S/AS02A.
Supporting Evidence
- Both vaccines were safe and had similar reactogenicity profiles.
- All subjects with paired pre and post-vaccination samples showed a vaccine response.
- Geometric mean titers for anti-CS antibodies were comparable between the two vaccine groups.
Takeaway
This study tested two versions of a malaria vaccine in young children and found that the new version is just as safe and effective as the old one.
Methodology
A phase I/IIb randomized double-blind study was conducted in Mozambique with 200 children aged 3 to 5 years receiving either RTS,S/AS02A or RTS,S/AS02D.
Potential Biases
Potential bias in participant selection and reporting of adverse events.
Limitations
The study was limited to a single center and focused only on safety and immunogenicity without assessing long-term efficacy.
Participant Demographics
200 healthy children aged 3 to 5 years, with equal representation of genders and all participants being Black.
Statistical Information
P-Value
0.9
Confidence Interval
95% CI 150–242
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website